The combination of magnetic resonance spectroscopy (MRS) and imaging (MRI) has led to mapping metabolites from normal and neoplastic tissue within the time limits of a routine study. MRSI (magnetic resonance spectroscopy imaging) detects metabolites that contain protons, phosphorus, fluorine, or other nuclei. This allows radiologists and oncologists to apply MRSI as an assessment of function (uptake) to supplement anatomic information in research and clinical practice.Magnetic resonance spectroscopy may be useful in some circumstances, such as assessing patient responses to neoadjuvant chemotherapy when resection has not yet been performed. It is not yet widely accepted that it can be used to successfully survey pateints at a high risk or relapse.
Jaffe, C. Carl Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design Oncologist 2008 13: 14-18
Vaidya SJ, Payne GS, Leach MO, Pinkerton CR. Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer. Eur J Cancer 2003;39:728–735